Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency
Background. The benefits of continuing antiretroviral therapy are questionable in human immunodeficiency virus (HIV) type 1–infected patients with profound immunodeficiency and multiple treatment failure due to viral resistance. Methods. From the French Hospital Database on HIV, we selected 12,765 p...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2008-01, Vol.46 (2), p.296-304 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 304 |
|---|---|
| container_issue | 2 |
| container_start_page | 296 |
| container_title | Clinical infectious diseases |
| container_volume | 46 |
| creator | Kousignian, Isabelle Abgrall, Sophie Grabar, Sophie Mahamat, Aba Teicher, Elina Rouveix, Elisabeth Costagliola, Dominique |
| description | Background. The benefits of continuing antiretroviral therapy are questionable in human immunodeficiency virus (HIV) type 1–infected patients with profound immunodeficiency and multiple treatment failure due to viral resistance. Methods. From the French Hospital Database on HIV, we selected 12,765 patients with a CD4+ cell count |
| doi_str_mv | 10.1086/524753 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03840431v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40306892</jstor_id><oup_id>10.1086/524753</oup_id><sourcerecordid>40306892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-ae101bf205a4e9256b5967f4a19012eb7bf99be8f31bc42be9e228abcac11b6b3</originalsourceid><addsrcrecordid>eNqF0d1u0zAUB_AIgdgY8AYgDwkkLgL-SmxfVt1Gi4oY3YbQbizHdai71C52Uuij8La4S9VKSIgLK0c5P_8d52TZcwTfIcjL9wWmrCAPsmNUEJaXhUAPUw0LnlNO-FH2JMYFhAhxWDzOjhBHDOGyPM5-f1LWtWlZ9x0MXGuDaYNf26AacD03Qa02YGpmnTYRtHMDpjbeAV-DwfjsKj8zdb_xfG1cG4F14FK19r7-ads5uHHau5TXNGYGvt6HTs2qsTop74ByM3AZfO27VIyXy875WYrUKUFvnmaPatVE82z3PMluLs6vh6N88vnDeDiY5Jryos2VQRBVNYaFokbgoqwKUbKaKiQgwqZiVS1EZXhNUKUprowwGHNVaaURqsqKnGRv-9y5auQq2KUKG-mVlaPBRG7fQcIppAStUbJversK_kdnYiuXNmrTNMoZ30XJIGIEl_i_EMOSUUZogq_-ggvfBZcuLDESggnExSFNBx9jMPX-OxGU2_HLfvwJvtylddXSzA5sN-8EXu-Ailo1dVBO23hwQnCaLpHcae98t_r3YS96s4itD3tFIYElF9t_kPd9G1vza99X4U6WjLBCjr7dyosrOoQf-Rd5S_4AJ23aag</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219979189</pqid></control><display><type>article</type><title>Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kousignian, Isabelle ; Abgrall, Sophie ; Grabar, Sophie ; Mahamat, Aba ; Teicher, Elina ; Rouveix, Elisabeth ; Costagliola, Dominique</creator><creatorcontrib>Kousignian, Isabelle ; Abgrall, Sophie ; Grabar, Sophie ; Mahamat, Aba ; Teicher, Elina ; Rouveix, Elisabeth ; Costagliola, Dominique ; Clinincal Epidemiology Group of the French Hosipital Database on HIV ; Clinical Epidemiology Group of the French Hospital Database on HIV ; the Clinical Epidemiology Group of the French Hospital Database on HIV</creatorcontrib><description>Background. The benefits of continuing antiretroviral therapy are questionable in human immunodeficiency virus (HIV) type 1–infected patients with profound immunodeficiency and multiple treatment failure due to viral resistance. Methods. From the French Hospital Database on HIV, we selected 12,765 patients with a CD4+ cell count <200 cells/mm3 who received a combination antiretroviral therapy (cART) during 2000–2005. Three groups of patients were defined: patients who interrupted cART at least once, patients who had at least 2 consecutive detectable viral loads (VLs) while receiving cART, and patients who had undetectable VL during treatment with cART. Incidence rates and risks of new acquired immunodeficiency syndrome-defining events (ADEs) were assessed among the 3 groups of patients, overall and after CD4+ cell count stratification (<50 and 50–200 cells/mm3). Results. The estimated incidence rates ± standard deviation of ADEs were 18.5±1.9, 14.5±0.7, and 4.9±0.5, respectively, for patients who interrupted cART, patients who had detectable VL during treatment with cART, and patients who had undetectable VL during treatment with cART. These differences were observed in both CD4+ cell count strata. Overall, after adjustment, risks of a new ADE in patients who had detectable VL and in patients who had undetectable VL while receiving cART were 22% and 62% lower, respectively, than in patients who stopped cART. Among patients with CD4+ cell count <50 cells/mm3, the risk of a new ADE was 22% lower in patients who continued to receive a failing cART regimen than in patients who stopped treatment with cART. Likewise, among patients with a CD4+ cell count of 50–200 cells/mm3, the risk was 34% lower in patients who continued to receive a failing cART regimen than in those who stopped taking cART. Conclusions. Even when effective virological control is no longer achievable, cART still reduces the risk of ADEs in profoundly immunodeficient HIV-infected patients.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/524753</identifier><identifier>PMID: 18171266</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acquired immune deficiency syndrome ; Acquired Immunodeficiency Syndrome - drug therapy ; Acquired Immunodeficiency Syndrome - immunology ; Acquired Immunodeficiency Syndrome - virology ; Adult ; AIDS ; Anti-Retroviral Agents - administration & dosage ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral drugs ; Antiretrovirals ; Antiviral agents ; Arts ; Biological and medical sciences ; Carts ; CD4 Lymphocyte Count - methods ; Cohort Studies ; Disease Progression ; Drug Combinations ; Drug therapy ; Female ; HIV ; HIV 1 ; HIV-1 - growth & development ; HIV-1 - physiology ; HIV/AIDS ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunology ; Immunopathology ; Infectious diseases ; Life Sciences ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prospective Studies ; Risk ; Risk Factors ; Santé publique et épidémiologie ; T lymphocytes ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load ; Virology ; Virus Replication ; Viruses</subject><ispartof>Clinical infectious diseases, 2008-01, Vol.46 (2), p.296-304</ispartof><rights>Copyright 2007 Infectious Diseases Society of America</rights><rights>2008 by the Infectious Diseases Society of America 2008</rights><rights>2008 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Jan 15, 2008</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-ae101bf205a4e9256b5967f4a19012eb7bf99be8f31bc42be9e228abcac11b6b3</citedby><cites>FETCH-LOGICAL-c485t-ae101bf205a4e9256b5967f4a19012eb7bf99be8f31bc42be9e228abcac11b6b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40306892$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40306892$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19984701$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18171266$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03840431$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kousignian, Isabelle</creatorcontrib><creatorcontrib>Abgrall, Sophie</creatorcontrib><creatorcontrib>Grabar, Sophie</creatorcontrib><creatorcontrib>Mahamat, Aba</creatorcontrib><creatorcontrib>Teicher, Elina</creatorcontrib><creatorcontrib>Rouveix, Elisabeth</creatorcontrib><creatorcontrib>Costagliola, Dominique</creatorcontrib><creatorcontrib>Clinincal Epidemiology Group of the French Hosipital Database on HIV</creatorcontrib><creatorcontrib>Clinical Epidemiology Group of the French Hospital Database on HIV</creatorcontrib><creatorcontrib>the Clinical Epidemiology Group of the French Hospital Database on HIV</creatorcontrib><title>Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Background. The benefits of continuing antiretroviral therapy are questionable in human immunodeficiency virus (HIV) type 1–infected patients with profound immunodeficiency and multiple treatment failure due to viral resistance. Methods. From the French Hospital Database on HIV, we selected 12,765 patients with a CD4+ cell count <200 cells/mm3 who received a combination antiretroviral therapy (cART) during 2000–2005. Three groups of patients were defined: patients who interrupted cART at least once, patients who had at least 2 consecutive detectable viral loads (VLs) while receiving cART, and patients who had undetectable VL during treatment with cART. Incidence rates and risks of new acquired immunodeficiency syndrome-defining events (ADEs) were assessed among the 3 groups of patients, overall and after CD4+ cell count stratification (<50 and 50–200 cells/mm3). Results. The estimated incidence rates ± standard deviation of ADEs were 18.5±1.9, 14.5±0.7, and 4.9±0.5, respectively, for patients who interrupted cART, patients who had detectable VL during treatment with cART, and patients who had undetectable VL during treatment with cART. These differences were observed in both CD4+ cell count strata. Overall, after adjustment, risks of a new ADE in patients who had detectable VL and in patients who had undetectable VL while receiving cART were 22% and 62% lower, respectively, than in patients who stopped cART. Among patients with CD4+ cell count <50 cells/mm3, the risk of a new ADE was 22% lower in patients who continued to receive a failing cART regimen than in patients who stopped treatment with cART. Likewise, among patients with a CD4+ cell count of 50–200 cells/mm3, the risk was 34% lower in patients who continued to receive a failing cART regimen than in those who stopped taking cART. Conclusions. Even when effective virological control is no longer achievable, cART still reduces the risk of ADEs in profoundly immunodeficient HIV-infected patients.</description><subject>Acquired immune deficiency syndrome</subject><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Acquired Immunodeficiency Syndrome - virology</subject><subject>Adult</subject><subject>AIDS</subject><subject>Anti-Retroviral Agents - administration & dosage</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretrovirals</subject><subject>Antiviral agents</subject><subject>Arts</subject><subject>Biological and medical sciences</subject><subject>Carts</subject><subject>CD4 Lymphocyte Count - methods</subject><subject>Cohort Studies</subject><subject>Disease Progression</subject><subject>Drug Combinations</subject><subject>Drug therapy</subject><subject>Female</subject><subject>HIV</subject><subject>HIV 1</subject><subject>HIV-1 - growth & development</subject><subject>HIV-1 - physiology</subject><subject>HIV/AIDS</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunology</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>Santé publique et épidémiologie</subject><subject>T lymphocytes</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><subject>Virology</subject><subject>Virus Replication</subject><subject>Viruses</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0d1u0zAUB_AIgdgY8AYgDwkkLgL-SmxfVt1Gi4oY3YbQbizHdai71C52Uuij8La4S9VKSIgLK0c5P_8d52TZcwTfIcjL9wWmrCAPsmNUEJaXhUAPUw0LnlNO-FH2JMYFhAhxWDzOjhBHDOGyPM5-f1LWtWlZ9x0MXGuDaYNf26AacD03Qa02YGpmnTYRtHMDpjbeAV-DwfjsKj8zdb_xfG1cG4F14FK19r7-ads5uHHau5TXNGYGvt6HTs2qsTop74ByM3AZfO27VIyXy875WYrUKUFvnmaPatVE82z3PMluLs6vh6N88vnDeDiY5Jryos2VQRBVNYaFokbgoqwKUbKaKiQgwqZiVS1EZXhNUKUprowwGHNVaaURqsqKnGRv-9y5auQq2KUKG-mVlaPBRG7fQcIppAStUbJversK_kdnYiuXNmrTNMoZ30XJIGIEl_i_EMOSUUZogq_-ggvfBZcuLDESggnExSFNBx9jMPX-OxGU2_HLfvwJvtylddXSzA5sN-8EXu-Ailo1dVBO23hwQnCaLpHcae98t_r3YS96s4itD3tFIYElF9t_kPd9G1vza99X4U6WjLBCjr7dyosrOoQf-Rd5S_4AJ23aag</recordid><startdate>20080115</startdate><enddate>20080115</enddate><creator>Kousignian, Isabelle</creator><creator>Abgrall, Sophie</creator><creator>Grabar, Sophie</creator><creator>Mahamat, Aba</creator><creator>Teicher, Elina</creator><creator>Rouveix, Elisabeth</creator><creator>Costagliola, Dominique</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><general>Oxford University Press (OUP)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20080115</creationdate><title>Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency</title><author>Kousignian, Isabelle ; Abgrall, Sophie ; Grabar, Sophie ; Mahamat, Aba ; Teicher, Elina ; Rouveix, Elisabeth ; Costagliola, Dominique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-ae101bf205a4e9256b5967f4a19012eb7bf99be8f31bc42be9e228abcac11b6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Acquired Immunodeficiency Syndrome - virology</topic><topic>Adult</topic><topic>AIDS</topic><topic>Anti-Retroviral Agents - administration & dosage</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretrovirals</topic><topic>Antiviral agents</topic><topic>Arts</topic><topic>Biological and medical sciences</topic><topic>Carts</topic><topic>CD4 Lymphocyte Count - methods</topic><topic>Cohort Studies</topic><topic>Disease Progression</topic><topic>Drug Combinations</topic><topic>Drug therapy</topic><topic>Female</topic><topic>HIV</topic><topic>HIV 1</topic><topic>HIV-1 - growth & development</topic><topic>HIV-1 - physiology</topic><topic>HIV/AIDS</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunology</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>Santé publique et épidémiologie</topic><topic>T lymphocytes</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><topic>Virology</topic><topic>Virus Replication</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kousignian, Isabelle</creatorcontrib><creatorcontrib>Abgrall, Sophie</creatorcontrib><creatorcontrib>Grabar, Sophie</creatorcontrib><creatorcontrib>Mahamat, Aba</creatorcontrib><creatorcontrib>Teicher, Elina</creatorcontrib><creatorcontrib>Rouveix, Elisabeth</creatorcontrib><creatorcontrib>Costagliola, Dominique</creatorcontrib><creatorcontrib>Clinincal Epidemiology Group of the French Hosipital Database on HIV</creatorcontrib><creatorcontrib>Clinical Epidemiology Group of the French Hospital Database on HIV</creatorcontrib><creatorcontrib>the Clinical Epidemiology Group of the French Hospital Database on HIV</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kousignian, Isabelle</au><au>Abgrall, Sophie</au><au>Grabar, Sophie</au><au>Mahamat, Aba</au><au>Teicher, Elina</au><au>Rouveix, Elisabeth</au><au>Costagliola, Dominique</au><aucorp>Clinincal Epidemiology Group of the French Hosipital Database on HIV</aucorp><aucorp>Clinical Epidemiology Group of the French Hospital Database on HIV</aucorp><aucorp>the Clinical Epidemiology Group of the French Hospital Database on HIV</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2008-01-15</date><risdate>2008</risdate><volume>46</volume><issue>2</issue><spage>296</spage><epage>304</epage><pages>296-304</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Background. The benefits of continuing antiretroviral therapy are questionable in human immunodeficiency virus (HIV) type 1–infected patients with profound immunodeficiency and multiple treatment failure due to viral resistance. Methods. From the French Hospital Database on HIV, we selected 12,765 patients with a CD4+ cell count <200 cells/mm3 who received a combination antiretroviral therapy (cART) during 2000–2005. Three groups of patients were defined: patients who interrupted cART at least once, patients who had at least 2 consecutive detectable viral loads (VLs) while receiving cART, and patients who had undetectable VL during treatment with cART. Incidence rates and risks of new acquired immunodeficiency syndrome-defining events (ADEs) were assessed among the 3 groups of patients, overall and after CD4+ cell count stratification (<50 and 50–200 cells/mm3). Results. The estimated incidence rates ± standard deviation of ADEs were 18.5±1.9, 14.5±0.7, and 4.9±0.5, respectively, for patients who interrupted cART, patients who had detectable VL during treatment with cART, and patients who had undetectable VL during treatment with cART. These differences were observed in both CD4+ cell count strata. Overall, after adjustment, risks of a new ADE in patients who had detectable VL and in patients who had undetectable VL while receiving cART were 22% and 62% lower, respectively, than in patients who stopped cART. Among patients with CD4+ cell count <50 cells/mm3, the risk of a new ADE was 22% lower in patients who continued to receive a failing cART regimen than in patients who stopped treatment with cART. Likewise, among patients with a CD4+ cell count of 50–200 cells/mm3, the risk was 34% lower in patients who continued to receive a failing cART regimen than in those who stopped taking cART. Conclusions. Even when effective virological control is no longer achievable, cART still reduces the risk of ADEs in profoundly immunodeficient HIV-infected patients.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>18171266</pmid><doi>10.1086/524753</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2008-01, Vol.46 (2), p.296-304 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03840431v1 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - immunology Acquired Immunodeficiency Syndrome - virology Adult AIDS Anti-Retroviral Agents - administration & dosage Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antiretrovirals Antiviral agents Arts Biological and medical sciences Carts CD4 Lymphocyte Count - methods Cohort Studies Disease Progression Drug Combinations Drug therapy Female HIV HIV 1 HIV-1 - growth & development HIV-1 - physiology HIV/AIDS Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunology Immunopathology Infectious diseases Life Sciences Male Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Risk Risk Factors Santé publique et épidémiologie T lymphocytes Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load Virology Virus Replication Viruses |
| title | Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A39%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maintaining%20Antiretroviral%20Therapy%20Reduces%20the%20Risk%20of%20AIDS-Defining%20Events%20in%20Patients%20with%20Uncontrolled%20Viral%20Replication%20and%20Profound%20Immunodeficiency&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Kousignian,%20Isabelle&rft.aucorp=Clinincal%20Epidemiology%20Group%20of%20the%20French%20Hosipital%20Database%20on%20HIV&rft.date=2008-01-15&rft.volume=46&rft.issue=2&rft.spage=296&rft.epage=304&rft.pages=296-304&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/524753&rft_dat=%3Cjstor_hal_p%3E40306892%3C/jstor_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219979189&rft_id=info:pmid/18171266&rft_jstor_id=40306892&rft_oup_id=10.1086/524753&rfr_iscdi=true |